Autolus raises $80 million in C financing

UK-based Autolus Ltd has secured $80 million in Series C capital from new and existing investors to advance the development of its engineered T cell therapies for cancer. The new investors include US-based Cormorant Asset Management and Nextech Invest of Switzerland.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom